Adagio Medical's Next-Gen Ablation Catheter Shows 50-75% Faster Procedure Times in Pre-Clinical Study — Adagio Medical Holdings, Inc.

Event summary

Adagio Medical published pre-clinical results for its next-generation ULTA ablation catheter in the Journal of Cardiovascular Electrophysiology on March 24, 2026.
The study showed potential for 50-75% reduction in ablation time compared to the first-generation vCLAS™ ULTA catheter.
The new 8.5 French-size catheter achieved 12.5-millimeter-deep lesions in approximately 120 seconds in pre-clinical models.
Physicians from leading ventricular ablation programs in Germany, Belgium, and Canada authored the study.

The big picture

Adagio Medical's next-generation ULTA technology aims to address the unmet needs of patients suffering from ventricular tachycardia (VT), a market segment that has seen limited innovation in ablation technologies. The company's focus on reducing procedure times and improving catheter handling could position it as a key player in the cardiac arrhythmia treatment space, particularly if the pre-clinical results are replicated in clinical trials. The strategic shift towards faster, single-freeze ablations with a smaller catheter aligns with broader industry trends toward minimally invasive and efficient cardiac procedures.

What we're watching

Clinical Translation: How quickly the pre-clinical results will translate into clinical practice and whether the 30-minute procedure time reduction claim holds in real-world settings.
Regulatory Pathway: The pace at which Adagio can advance its FULCRUM-VT U.S. Pivotal IDE Trial, given the promising pre-clinical data.
Market Adoption: Whether the smaller, more maneuverable catheter will drive broader adoption of ULTA technology among electrophysiologists.